对于全身性青少年异常性关节炎的阿巴切的疗效和安全性:系统性审查
相关实验视频
Updated: Jun 26, 2025

08:36
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
1.1K
Kenichi Nishimura1, Takashi Ishikawa2,3, Nami Okamoto4
1Department of Pediatrics, Yokohama City University Graduate School of Medicine, Kanagawa, Japan.
Modern rheumatology
|May 16, 2024
概括
阿巴塞普改善了系统性青少年异常性关节炎 (JIA) 的疾病活性. 虽然通常是安全的,但证据质量较低,需要进一步研究其对关节症状的有效性.
科学领域:
- 类风湿病学 类风湿病学
- 儿科风湿病学 儿科风湿病学
- 免疫学 免疫学 免疫学
背景情况:
- 系统性青少年异常性关节炎 (JIA) 是一种严重的自身免疫性疾病,需要有效的治疗.
- 阿巴塔塞普特是一种T细胞共刺激调节剂,是JIA的潜在治疗选择.
研究的目的:
- 系统地审查系统性JIA患者的阿巴塔塞普特的疗效和安全性.
- 根据既定标准评估治疗反应.
- 评估与阿巴cept治疗相关的不良事件.
主要方法:
- 在主要数据库 (PubMed,Embase,Cochrane等) 进行了系统的文献搜索. 和临床试验注册表.
- 包括2000年至2021年间发表的研究.
- 使用临床实践指南的Minds手册来评估偏差风险.
主要成果:
- 七项观察性研究被纳入了审查.
- 在美国风湿病学学院的儿科响应标准中,阿巴塔塞普在3,6个月和12个月后有所改善.
- 没有报告巨细胞激活综合征或输液反应的病例;严重感染发生在2.6%的患者中.
结论:
- 阿巴切在改善系统性JIA的疾病活性指数方面表现出有效性.
- 安全性概况似乎与IL-6和IL-1抑制剂相当.
- 低到非常低的证据质量需要谨慎的解释;需要进一步的研究,特别是关节症状疗效.
相关概念视频
The JAK-STAT Signaling Pathway
8.8K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.8K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
131
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
131

